RHHVF - What's Going On Cancer Player Monte Rosa Therapeutics Stock Today? | Benzinga
Monte Rosa Therapeutics Inc (NASDAQ: GLUE) entered into a strategic collaboration and licensing agreement with Roche Holdings AG (OTC: RHHBY) to discover and develop molecular glue degraders (MGDs) against targets in cancer and neurological diseases.
Under the terms of the agreement, Monte Rosa will receive an upfront payment of $50 million and is eligible to receive future milestone payments that could exceed $2 billion, as well as tiered royalties.
The parties also agreed on a mechanism to expand the collaboration on multiple targets within the ...